Nav: Home

More evidence in quest to repurpose cancer drugs for Alzheimer's disease

July 27, 2016

TORONTO - An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases when given to animals. This finding is the latest from Georgetown University Medical Center's Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.

The study, to be presented at the annual Alzheimer's Association International Conference in Toronto, found that the drug pazopanib decreases levels of phosphorylated Tau (p-Tau) in animal models genetically engineered to produce human mutant tau throughout their brains.

The TNP lab previously demonstrated in animal models that tau is a critical part of the "garbage disposal system," in cells allowing them to clear accumulated toxic proteins. In humans, p-Tau describes tau that has been abnormally modified, leaving it unable to do its job.

"Our lab has shown that functional tau is required for the clearance of amyloid beta, which accumulates in sticky clumps called plaques. If tau stops functioning, the amyloid beta accumulation leads to cell death," explains Monica Javidnia, a pharmacology doctoral candidate at GUMC. "When tau is abnormally modified, it accumulates within neurons forming sticky tangles, and the when the cell dies, it and the amyloid beta spill out into the brain. These are the plaques and tangles that are the hallmark of Alzheimer's disease." P-tau is also involved in other neurodegenerative diseases.

Previous research from the TNP has shown that when tyrosine kinases are inhibited, the garbage disposal system begins working, allowing cells to once again clear toxic proteins. Pazopanib is a known tyrosine kinase inhibitor.

The TNP, led by Charbel Moussa, MD, PhD, has identified several tyrosine kinase, which appear to play a role in neurodegeneration, protein clearance and inflammation. This work has led to clinical trials with the cancer drug nilotinib in both Parkinson's and Alzheimer's disease set to begin this summer. (Moussa is listed as an inventor on a patent application that Georgetown University filed related to nilotinib and the use of other tyrosine kinase inhibitors for the treatment of neurodegenerative diseases.)

As Javidnia explains, there are two schools of thought in the Alzheimer's field as to the main culprit of the disease -- tau or amyloid beta.

"Work from our lab and other groups shows tau pathology preceding amyloid beta. We believe tau is mainly responsible for dementia and exacerbates A-beta pathology," she says. "However, we are also studying the effects of pazopanib on amyloid beta to create a better understanding of how it works and what diseases it could potentially be used to treat."

Javidnia says analysis in this study shows pazopanib penetrates the mice's blood-brain barrier when given the equivalent of half of dose given for renal cell carcinoma treatment. Following treatment, the animal models showed significant decreases in levels of phosphorylated tau.

"In addition, the drug was safe and well-tolerated," Javidnia says. "Our next work will focus on the individual receptors pazopanib targets to better understand their role in protein clearance and inflammation."
Javidnia's co-authors include Moussa, Michaeline Hebron and Hannah J Brown from the TNP.

About Georgetown University Medical Center

Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health. Connect with GUMC on Facebook (, Twitter (@gumedcenter) and Instagram (@gumedcenter).

Georgetown University Medical Center

Related Amyloid Beta Articles:

Gene variant protecting against Alzheimer's disease decreases plasma beta-amyloid levels
New research from the University of Eastern Finland shows that the APP gene variant protecting against Alzheimer's disease significantly decreases plasma beta-amyloid levels in a population cohort.
More amyloid in the brain, more cognitive decline
A new study from the Center for Vital Longevity at The University of Texas at Dallas has found that the amount of amyloid plaques in a person's brain predicts the rate at which his or her cognition will decline in the next four years.
Elevated brain amyloid level associated with increased likelihood of cognitive decline
Among a group of cognitively normal individuals, those who had elevated levels in the brain of the protein amyloid were more likely to experience cognitive decline in the following years, according to a study published by JAMA.
Alzheimer's: Proteomics gives clues toward alternatives to amyloid
In Alzheimer's research, one particular protein looms large: plaque-forming amyloid-beta.
New drug helps clear amyloid plaques in Alzheimer's disease patients
New research suggests a long-sought amyloid-lowering drug for Alzheimer's disease may soon be on the horizon.
Antibody reduces harmful brain amyloid plaques in Alzheimer's patients
Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease.
Vesicles that trap amyloid appear to also contribute to Alzheimer's
Vesicles, fluid-filled sacs that brain cells make to trap amyloid, a hallmark of Alzheimer's, appear to also contribute to the disease, scientists report.
Amyloid-related heart failure now detectable with imaging test
A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study led by researchers at Columbia University Medical Center.
New research adds evidence on potential treatments targeting amyloid beta in Alzheimer's
New research findings from the Center for Cognitive Neurology at NYU Langone Medical Center could provide additional clues for future treatment targets to delay Alzheimer's disease and related dementias.
Amyloid probes gain powers in search for Alzheimer's cause
A synthetic molecule with a rhenium core glows when attached to an amyloid fibril in the process of aggregating into a plaque, and brighter still when hit with ultraviolet light.

Related Amyloid Beta Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...